Se connecter

Bibliographies thématiques / Cisplatin / Livres

Livres sur le sujet « Cisplatin »

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Cisplatin.

Auteur : Grafiati

Publié le 4 juin 2021

Mis à jour le 6 juillet 2024

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs livres pour votre recherche sur le sujet « Cisplatin ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les livres sur diverses disciplines et organisez correctement votre bibliographie.

1

Ozols, Robert F. High-dose Platinol (cisplatin for infection) in hypertonic saline. Syracuse, N.Y : Bristol-Myers Oncology Division, 1985.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Chu, Wendy. Mechanism of cisplatin resistance inhuman malignant melanoma. Ottawa : National Library of Canada, 1998.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Yoshihiro, Kikuchi, dir. Mechanism of cisplatin resistance and its circumvention. Commack, NY : Nova Science Publishers, 1998.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Merazga, Yamina. Aspects of the interaction between cisplatin and renal glutathione. Uxbridge : Brunel University, 1990.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

1946-, Lippert Bernhard, dir. Cisplatin : Chemistry and biochemistry of a leading anticancer drug. Zürich : Verlag Helvetica Chimica Acta, 1999.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Morley, Christopher. Analogues of cisplatin from diamino carbohydrates and related compounds. Norwich : University of East Anglia, 1986.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Evans, Dyfed Llyr. The induction of apoptosis by the anticancer agent cisplatin. Manchester : Universityof Manchester, 1994.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Laurell, Göran. Ototoxicity of the anticancer drug cisplatin : Clinical and experimental aspects. Stockholm, Sweden : Distributed by Almqvist & Wiksell Periodical Co., 1991.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pembrolizumab (nicht kleinzelliges Lungenkarzinom : Nutzenbewertung gemäß § 35a SGB V. Köln : Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, 2017.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Bryant, Eric Edward. Systems Genetics of DNA Damage Tolerance – Cisplatin, RAD5 & CRISPR-mediated Nonsense. [New York, N.Y.?] : [publisher not identified], 2019.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

Kuduk-Jaworska, Janina. Przeciwnowotworowo aktywne kompleksy platyny. Wrocław : Wydawn. Uniwersytetu Wrocławskiego, 1992.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

International, Congress on Neo-Adjuvant Chemotherapy (2nd 1987 Paris France). Paraplatine : Carboplatine : symposium satellite du deuxième congrès international sur la chimiothérapie néo-adjuvante Paris, 20 frévier 1988. Paris : Libbey Eurotext, 1988.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

13

M, Beard S., et Trent Institute for Health Services Research. Working Group on Acute Purchasing., dir. The use of cisplatin and paclitaxel as a first line treatment in ovarian cancer. Sheffield : Trent Institute for Health Services Research, 1997.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

Kuzniar, Beata. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity. Ottawa : National Library of Canada, 1998.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

15

Weinrib, Laura M. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma. Ottawa : National Library of Canada, 2000.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

16

Obasaju, Coleman Kehinde. Methotrexate and cisplatin pharmacokinetics when used as neoadjuvant treatment in patients with poor progress cervical cancer. Manchester : University of Manchester, 1995.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

17

Malinowski, Jerzy. Sztuka i nowa wspólnota : Zrzeszenie Artystów Bunt, 1917-1922. Wrocław : "Wiedza o Kulturze", 1991.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

18

H, McBrien D. C., et Slater T. F, dir. Biochemical mechanisms of platinum antitumour drugs : Based on the proceedings of a symposium held at Brunel University, 3-5th July 1985. Oxford : IRL, 1986.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

19

H, McBrien D. C., et Slater T. F. 1931-, dir. Biochemical mechanisms of platinum antitumour drugs : Based on the proceedings of a symposium held at Brunel University, July 3-5, 1985. Oxford : IRL, 1986.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Souzamotta, Nando. Cisplatino versus Mandinga ! Montevideo : Zignone Comics, 2011.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Cabrelli, Matias. Presencia masónica en la Cisplatina. [Montevideo] : América Una, 1986.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Cabrelli, Alfonso Fernández. Presencia masónica en la Cisplatina. [Montevideo] : América Una, 1986.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

23

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (5th 1987 Padua, Italy). Platinum and other metal coordination compounds in cancer chemotherapy : Proceedings of the Fifth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Abano Padua, Italy, June 29-July 2, 1987. Boston : Nijhoff, 1988.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

R, Kelland Lloyd, et Farrell Nicholas 1948-, dir. Platinum-based drugs in cancer therapy. Totowa, N.J : Humana Press, 2000.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

25

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (7th 1995 Amsterdam, Netherlands). Platinum and other metal coordination compounds in cancer chemotherapy 2. New York : Plenum Press, 1996.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

26

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (6th 1991 San Diego, Calif.). Platinum and other metal coordination compounds in cancer chemotherapy. New York : Plenum Press, 1991.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

27

Barroso, Gustavo. A Guerra do Vidéo : 1825-1828 : contos e episódios da Campanha da Cisplatina. [Fortaleza, Brazil] : UFC, Casa de José de Alencar, Programa Editorial, 2000.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

28

Canez, Anna Paula. Arquiteturas cisplatinas : Roman Fresnedo Siri e Eladio Dieste em Porto Alegre. Porto Alegre, RS : UniRitter, Centro Universitário Ritter dos Reis, Faculdade de Arquitetura e Urbanismo, 2004.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

29

Lippert, Bernhard, dir. Cisplatin. Wiley, 1999. http://dx.doi.org/10.1002/9783906390420.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

30

Brock, Patrick. Cisplatin Toxicity in Infants and Children. Leuven University Press, 1994.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

31

Prestayko, Archie W. Cisplatin : Current Status and New Developments. Elsevier Science & Technology Books, 2013.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

32

Kojima, Toshiko, et Yoko Morita. Cisplatin : Pharmacology, Clinical Uses and Adverse Effects. Nova Science Publishers, Incorporated, 2012.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

33

Bongers, Jacob. Platinum(II) metallothioneins. 1989.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

34

Lippert, Bernhard. Cisplatin : Chemistry and Biochemistry of a Leading Anticancer Drug. Wiley-VCH, 1999.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

35

Lippert, Bernhard. Cisplatin : Chemistry and Biochemistry of a Leading Anticancer Drug. Wiley & Sons, Limited, John, 2006.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

36

Publications, ICON Health. Cisplatin - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

37

Clinical and Preclinical Pharmacokinetic and Dynamic Studies with Cisplatin, Topotecan and Docetaxel. ICG Printing, 1996.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

38

Ajithkumar, Thankamma, Ann Barrett, Helen Hatcher et Natalie Cook. Appendix. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235636.003.0022.

Texte intégral

Résumé :

Systemic therapy regimens 692Radiotherapy fractionation 695Glomerular filtration rate 701Anatomical diagrams 702• Cisplatin 80–100mg/m2 IV infusion Day 1• 5-FU 1g/m2 24-hour infusion Days 1–5• 3-week cycle• 75mg/m2 for 42 days starting on the first day of radiotherapy. Give 1 hour prior to radiotherapy and morning at weekend...

Styles APA, Harvard, Vancouver, ISO, etc.

39

Pinkett, Georgia L. Cisplatinum : An antineoplastic agent with an ototoxic effect. 1991.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

40

McBrien, D. C. H. Biochemical Mechanisms of Platinum Antitumour Drugs. Oxford University Press, USA, 1985.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

41

(Editor), Lloyd R. Kelland, et Nicholas P. Farrell (Editor), dir. Platinum-Based Drugs in Cancer Therapy (Cancer Drug Discovery and Development). Humana Press, 2000.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

42

(Editor), Donald Henderson, Richard J. Salvi (Editor), Antonio Quaranta (Editor) et et al (Editor), dir. Ototoxicity : Basic Science and Clinical Applications (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1999.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

43

Calabrò, Fabio, et Cora N. Sternberg. Treatment of metastatic bladder cancer. Sous la direction de James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0079.

Texte intégral

Résumé :

Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led to clinical investigation of several therapeutic targets. To date, these agents have yet to demonstrate an improvement in overall survival. Urothelial cancer is extremely sensitive to checkpoint inhibition with both anti PD-1 and anti PDL1 antibodies. The future seems brighter with the advent of these new therapies.

Styles APA, Harvard, Vancouver, ISO, etc.

44

Ball, Steve, et Sajid Kalathil. Adrenocortical cancer. Sous la direction de James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0094.

Texte intégral

Résumé :

Adrenocortical cancer (ACC) is rare and associated with poor prognosis. The incidence is estimated at 0.7–2 cases per one million. Overall survival rate at five years for ACC is 37–47%. While the pathogenesis of ACC is incompletely understood, inherited predisposition syndromes are common in childhood ACC. Clinical presentation can be with symptoms and signs of hormone excess (functional tumours), mass effects, or as an incidental radiological finding. A multidisciplinary approach combining radiology, biochemistry, and tissue-based pathology is needed to establish a diagnosis to guide a surgical approach aimed at complete resection of the tumour where possible. At present, recommended first-line therapies for advanced disease are mitotane monotherapy or etopiside, doxorubicin, and cisplatin plus mitotane. Metronomic capecitabine and gemcitabine have been used as alternatives. Adjuvant radiotherapy to the tumour bed should be considered for patients considered to be at high risk of recurrence.

Styles APA, Harvard, Vancouver, ISO, etc.

45

Hoskin, Peter. Vulva and vagina. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199696567.003.0014.

Texte intégral

Résumé :

Chapter 9b discusses carcinoma of the vulva, which is primarily a surgical disease best treated by wide surgical resection, radical vulvectomy, and inguinal lymph node dissection based on presenting stage. Rarely, locally advanced primary disease may be presented for primary radiotherapy treatment. Postoperative radiotherapy is recommended for tumours invading >7 mm in a vertical direction. The first station regional lymph nodes in the inguinal region are best treated by radical surgical dissection, but fixed inoperable lymph nodes may benefit from primary radiotherapy which may be followed where appropriate by surgery if there is a residual mass. Postoperative radiotherapy should be considered for women having more than one node involved with metastatic tumour at surgery. This must be balanced against the increased risk of lymphoedema where both surgery and radiotherapy are delivered to the groins. Chemoradiation using cisplatin or 5-FU/mitomycin C-based schedules has been reported but no randomized comparison with radiotherapy alone has been undertaken; whilst high response rates are seen there is a considerable increase in acute toxicity.

Styles APA, Harvard, Vancouver, ISO, etc.

46

Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer, 1996.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

47

D, Ahlgren James, Rotman Marvin 1933- et Rosenthal C. Julian, dir. Concomitant continuous infusion chemotherapy and radiation. Berlin : Springer-Verlag, 1991.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

48

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff et Madhumita Bhattacharyya. Breast cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0014_update_001.

Texte intégral

Résumé :

Thoracic cancer examines the epidemiology, aetiology, and role of screening and prevention in the reduction of deaths from lung cancer, the majority caused by cigarette smoking. The pathology and genetics of lung cancer, with particular note of the driver mutations, are followed by the symptoms and signs of the disease. Appropriate investigations are described to stage the tumour. The optimum treatment for localised non-small cell lung cancer (NSCLC) is surgical resection, followed in some cases by adjuvant chemotherapy. However, most cases present with disease too advanced for surgery, and for these chemotherapy and radiotherapy are appropriate. Metastatic NSCLC can be treated with platinum based doublet chemotherapy with modest palliative benefits. Metastatic NSCLC with specific driver mutations are amenable to control by targeted therapy. Locally advanced NSCLC is often treated with similar chemotherapy and radiotherapy, ideally administered concurrently, to achieve symptom relief but also improved survival rates. Short course simple radiotherapy offers symptom relief in patients not fit for chemotherapy. Patients with localised NSCLC who are not fit for surgery, may benefit from radical radiotherapy, particularly stereotactic radiotherapy. Small cell lung cancer (SCLC) is characterised by almost universal systemic spread, so that surgery is rarely appropriate. Staging is similar to NSCLC, and chemotherapy is the mainstay of treatment, usually cisplatin or carboplatin combined with etoposide. When possible, this is combined with concurrent thoracic irradiation covering all radiological sites of disease. Prophylactic cranial irradiation reduces the risk of CNS disease. Malignant pleural mesothelioma is caused by occupational asbestos exposure. Symptoms and signs, investigation and staging, and management are discussed. Thymic tumours, their pathology, presenting symptoms including paraneoplastic syndromes, investigation, staging and treatment are reviewed.

Styles APA, Harvard, Vancouver, ISO, etc.

49

Brady, L. W., C. Julian Rosenthal, Marvin Rotman et H. P. Heilmann. Concomitant Continuous Infusion Chemotherapy and Radiation. Springer London, Limited, 2012.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

50

Brady, L. W., C. Julian Rosenthal, Marvin Rotman et H. P. Heilmann. Concomitant Continuous Infusion Chemotherapy and Radiation. Springer London, Limited, 2012.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!